Table 2.
Distribution of patients with at least 1 adverse event (AE) by gender and type of biotech drug.
| Total | Female | Male | Chi-square test (P-value) | ||||
|---|---|---|---|---|---|---|---|
| N. users | N. with AEs (%) | N. users | N. with AEs (%) | N. users | N. with AEs (%) | ||
| Patients | 775 | 320 (41.29) | 417 | 172 (41.2) | 358 | 148 (41.3) | 0.364 |
| BIOLOGICS | |||||||
| Rituximab | 154 | 81 (52.60) | 64 | 37 (57.81) | 90 | 44 (48.89) | 0.880 |
| Cetuximab | 63 | 43 (68.25) | 15 | 13 (86.67) | 48 | 30 (62.50) | 0.433 |
| Bevacizumab | 93 | 40 (43.01) | 52 | 22 (42.31) | 41 | 18 (43.90) | 0.277 |
| Infliximab | 83 | 37 (44.58) | 30 | 14 (46.67) | 53 | 23 (43.40) | 0.556 |
| Trastuzumab* | 69 | 33 (47.83) | 63 | 30 (47.62) | 6 | 3 (50.00) | 0.224 |
| Adalimumab | 66 | 16 (24.24) | 39 | 14 (35.90) | 27 | 2 (7.41) | < 0.001 |
| Golimumab | 33 | 4 (12.12) | 17 | 3 (17.65) | 16 | 1 (6.25) | 0.063 |
| Denosumab | 24 | 1 (4.17) | 15 | – | 9 | 1 (11.11) | – |
| Etanercept | 49 | 10 (20.41) | 29 | 8 (27.59) | 20 | 2 (10.00) | 0.023 |
| Tocilizumab | 36 | 8 (22.22) | 35 | 8 (22.86) | 1 | – | – |
| Other biologics$ | 105 | 47 (34.31) | 58 | 23 (25.00) | 47 | 24 (53.33) | < 0.001 |
*
Including trastuzumab emtansine.
$
Including: abatacept, panitumumab, certolizumab pegol, natalizumab, ustekinumab, pertuzumab, aflibercept, brentuximab vedotin, belimumab, anakinra, brentuximab vedotin, eculizumab, ramucirumab, romiplostin, eculizumab.